2014


To access this material please log in or register

Register Authorize
2014/№4

Compliance with antiplatelet therapy of patients with high comorbidity

Efremova E. V., Shutov A. M.

Keywords: antiaggregates, comorbidity, therapy compliance, cardiovascular diseases

DOI: 10.18087/rhj.2014.4.1990

Background. In recent years, presence of comorbidity and formation of patients’ satisfactory compliance with the administered treatment has been growing in importance for therapy and diagnostics. Antiplatelet therapy is an essential component of the multi-modality management of cardiology patients. Aim. To study compliance with the antiplatelet therapy of highly comorbid patients. Materials and methods. 203 patients with CHF (130 males and 73 females aged 61.8±9.6 years) participated in the study. Comorbidity, quality of life, personal characteristics, and compliance of comorbid patients with the antiplatelet therapy were evaluated. Results. The Charlson comorbidity index was 5.0±2.1. 98 (51.3 %) patients were compliant with the antiplatelet therapy. Patients with poor compliance were characterized with disadaptive obsessive-phobic type of attitude to their disease (χ2=6.22; р=0.01) and the «projection» psychic defense mechanism (р=0.02). Among patients with high compliance with the treatment, the emotive type of character accentuation prevailed (р<0.001). Conclusion. The presence of comorbidity results in administration of antiplatelet therapy to patients with CHF. Low compliance with the antiplatelet therapy is due to personality features of CHF patients.
  1. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  3. Bayliss EA, Steiner JF, Fernald DH et al. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med. 2003;1 (1):15–21.
  4. Dickson VV, Buck H, Riegel B. A qualitative meta-analysis of heart failure self-care practices among individuals with multiple comorbid conditions. J Card Fail. 2011;17 (5):413–419.
  5. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007 Jun;93 (6):665–71.
  6. Salisbury C, Johnson L, Purdy S et al. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2011;61 (582):e12–21.
  7. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of di­sease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004 Dec 30;351 (27):2870–4.
  8. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008 Jul;42 (7):1017–25.
  9. Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22 (9):767–77.
  10. Калягин А. Н. Хроническая сердечная недостаточность: современное состояние проблемы. Особенности ведения пожилых больных. Сибирский медицинский журнал.2008;78 (3):114–119.
  11. Erlikh AD, Gratsianskiĭ NA. Registry of acute coronary syndromes RECORD. Characteristics of patients and results of inhospital treatment. Kardiologiia. 2009;49 (7-8):4–12.
  12. Gorelick PB, Farooq MU. Advances in our understanding of «resistance» to antiplatelet agents for prevention of ischemic stroke. Stroke Res Treat. 2013;2013:727842.
  13. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119 (23):3028–3035.
  14. Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association. Stroke. 2013 Mar;44 (3):870–947.
  15. Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333 (7557):15.
  16. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. Нефрология. 2012;16 (1):91–108.
  17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40 (5):373–383.
  18. Петрик Е. А. Особенности полиморбидности у соматических больных. Автореф. дис.…канд. мед наук: 14.00.05. − М., 2011. – 25c.
  19. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scores: a user's manual. Boston, MA: The Health Institute. New England Medical Center. 1994.
  20. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24 (1):67–74.
  21. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12 (3):189–198.
  22. Личко А. Е., Иванов Н. Я. Методика определения типа отношения к болезни.Журнал невропатологии и психиатрии. 1980;8:1527–1530.
  23. Леонгард К. Акцентуированные личности. – Ростов н / Д.: Изд-во Феникс, 2000. – 544 с.
  24. Plutchik R, Kellerman H, Conte HR. A structural theory of ego defenses and emotions. In C. E. Izard (Ed.), Emotions in persona­lity and psychopathology. – N. Y. Plenum, 1979. – p.229–257.
  25. Cox L, Kloseck M, Crilly R et al. Underrepresentation of indivi­duals 80 years of age and older in chronic disease clinical practice guidelines. Can Fam Physician. 2011 Jul;57 (7):e263–9.
  26. Mutasingwa DR, Ge H, Upshur RE. How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician. 2011 Jul;57 (7):e253–62.
  27. Kahn LS, Fox CH, Olawaiye A et al. Facilitating quality improvement in physician management of comorbid chronic disease in an urban minority practice. J Natl Med Assoc. 2007 Apr;99 (4):377–83.
  28. Alberts MJ, Bhatt DL, Mas JL et al, for the REACH Registry Investigators. Three-year follow up and event rates in the international Reduction of Atherothrombosis for Coronary Health Registry. Eur Heart J. 2009;30 (19):2318–2236.
  29. Пучиньян Н. Ф., Довгалевский Я. П., Долотовская П. В., и др. Приверженность рекомендованной терапии больных, перенесших острый коронарный синдром, и риск развития сердечно-сосудистых осложнений в течение года после госпитализации. Рациональная Фармакотерапия в Кардиологии. 2011;7 (5) 567–573.
  30. Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25 (2):166–181.
  31. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;271 (18):1450–1456.
  32. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120 (16):1598–1605.
  33. Francisco AR, Sousa M, Amador P et al. Chronic medical comorbidities in patients with acute coronary syndrome. Rev Port Cardiol. 2010 Jan;29 (1):7–21.
  34. Конради А. О. Значение приверженности, к терапии в лечении кардиологических заболеваний. Справочник поликлинического врача. 2007;4 (6):21–25.
  35. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment Eur. Heart J. 2003;24 (5):464–474.
  36. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. От имени рабочей группы исследования ЭПОХА–О–ХСН. Сравнительная характеристика больных ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН. Журнал Сердечная Недостаточность. 2006;7 (4):164–171.
  37. de Leon CF, Grady KL, Eaton C et al. Quality of life in a diverse population of heart failure patients:Baseline findings from the Heart Failure Adherence and Retention Trial (HART). J Cardiopulm Rehabil Prev. 2009;29 (3):171–178.
  38. Кошелева Н. А. Хроническая сердечная недостаточность ишемического генеза: клинико-функциональные взаимоотношения, прогнозирование течения, возможности терапии. Автореф. дис… д-ра. мед. наук 14.01.05. – Саратов, 2012. – 48 с.
  39. Альберт М. А., Биктимиров Т. З., Шутов А. М. Приверженность к лечению и личностные особенности больных хронической сердечной недостаточностью. Ученые записки Ульяновского государственного университета. 2008;1 (13):6–9.
Efremova E. V., Shutov A. M. Compliance with antiplatelet therapy of patients with high comorbidity. Russian Heart Journal. 2014;78 (4):199–205

To access this material please log in or register

Register Authorize
Ru En